Theratechnologies Announces Financial Results for Second Quarter of 2014
Marketwire - Wed Jul 09, 5:45AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the second quarter ended May 31, 2014.
Theratechnologies to Announce Financial Results for the Second Quarter of 2014
Marketwire - Wed Jul 02, 3:20PM CDT
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the second quarter ended May 31, 2014, on Wednesday, July 9, 2014, before markets open.
IIROC Trade Halt - Theratechnologies Inc.
Newsfile Corp - Wed Jun 25, 8:23AM CDT
The following issues have been halted by IIROC:
IIROC Trade Resumption - Theratechnologies Inc.
Newsfile Corp - Wed Jun 25, 8:17AM CDT
Trading resumes in:
Theratechnologies to Receive 4.1 Million Dollar Payment from Revenue Canada
Marketwire - Wed Jun 25, 8:05AM CDT
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will receive a refund of approximately $4.1 million from the Canada Revenue Agency after settling a dispute over its claims of refundable investment tax credits related to its 1994 and 1995 taxation years.
Theratechnologies Announces Financial Results for Fiscal Year 2013
Marketwire - Thu Feb 27, 6:02AM CST
Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the year ended November 30, 2013.
Theratechnologies to Announce Financial Results for Fiscal Year 2013
Marketwire - Tue Feb 25, 4:01PM CST
Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the fiscal year ended November 30, 2013, on Thursday, February 27, 2014, before markets open.
Theratechnologies Inc.: Short Supply of EGRIFTA(R) Announced
Marketwire - Fri Feb 14, 5:01AM CST
Theratechnologies Inc. (TSX: TH) announced today that it expects current inventory of EGRIFTA(R) (tesamorelin for injection) to be depleted in the coming weeks due to a combination of manufacturing delays and issues observed during the production of new batches of EGRIFTA(R). The depletion of the inventory will result in a shortage of EGRIFTA(R) and an eventual stock-out. EMD Serono, Inc. has notified the United States Food and Drug Administration about this product shortage.
EMD Serono Notifies FDA of a Shortage of Tesamorelin
Marketwire - Wed Sep 18, 4:38PM CDT
Theratechnologies Inc. (TSX: TH) announced today that EMD Serono voluntarily notified the United States Food and Drug Administration (FDA) about an upcoming shortage of tesamorelin in the United States.
Theratechnologies Provides Manufacturing Update on EGRIFTA(TM)
Marketwire - Wed Sep 04, 4:22PM CDT
Theratechnologies Inc. (TSX: TH) announced today that it will resume production of EGRIFTA(TM) using its original manufacturing process (original process).
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Theratechnologies Inc.: Securities Class Action Update
Marketwire - Wed Jul 17, 5:01PM CDT
Theratechnologies Inc. (TSX: TH) announced today that the Court of Appeal of Quebec has dismissed Theratechnologies' motion to dismiss the authorization to institute a class action and an action based on the secondary market liability provisions of the Securities Act (Quebec) against Theratechnologies, a former Chair of the Board of Directors and a former president and chief executive officer.